Cargando…

DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml

BACKGROUND: This study investigated the diagnostic utility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) parameters for distinguishing between benign and malignant prostate tumors when serum prostate-specific antigen (PSA) level is ≥10 ng/ml....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Hongmei, Du, Fengli, Liu, Yan, Li, Qian, Liu, Xinai, Wang, Tongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792168/ https://www.ncbi.nlm.nih.gov/pubmed/36578948 http://dx.doi.org/10.3389/fonc.2022.925186

Ejemplares similares

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer
por: Ma, Xiang-Zheng, et al.
Publicado: (2019)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
por: Johnson, Michael H., et al.
Publicado: (2015)

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL
por: Lu, Yangbai, et al.
Publicado: (2022)

DCE-MRI and DWI Integration for Breast Lesions Assessment and Heterogeneity Quantification
por: Méndez, C. Andrés, et al.
Publicado: (2012)

Predictive effect of DCE-MRI and DWI in brain metastases from NSCLC
por: Ye, Chengyu, et al.
Publicado: (2021)

Predictive value of DCE-MRI and IVIM-DWI in osteosarcoma patients with neoadjuvant chemotherapy
por: Xia, Xibin, et al.
Publicado: (2022)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml(-1) and 10.1–20.0 ng ml(-1): a multicenter study
por: Lin, Yu-Rong, et al.
Publicado: (2015)

Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL
por: Lee, Dong Hoon, et al.
Publicado: (2017)

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL
por: Lee, Dong Hoon, et al.
Publicado: (2016)

Dynamic Contrast Magnetic Resonance Imaging (DCE-MRI) and Diffusion Weighted MR Imaging (DWI) for Differentiation between Benign and Malignant Salivary Gland Tumors
por: Assili, S., et al.
Publicado: (2015)

Combination of DCE-MRI and DWI in Predicting the Treatment Effect of Concurrent Chemoradiotherapy in Esophageal Carcinoma
por: Liu, Changmin, et al.
Publicado: (2020)

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA
por: Zhao, Jing, et al.
Publicado: (2016)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml(−1))
por: Liu, Jun, et al.
Publicado: (2019)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml
por: Chavan, Sushant V., et al.
Publicado: (2011)

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
por: Adegun, Patrick Temi, et al.
Publicado: (2015)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
por: Busato, W. F. S., et al.
Publicado: (2015)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

Predicting prostate cancer in men with PSA levels of 4–10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance
por: Zhong, Jian-Guo, et al.
Publicado: (2023)

Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China
por: Dai, Zhihong, et al.
Publicado: (2021)

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
por: Su, Rui, et al.
Publicado: (2022)

Multiparameter MRI Model With DCE-MRI, DWI, and Synthetic MRI Improves the Diagnostic Performance of BI-RADS 4 Lesions
por: Sun, Shi Yun, et al.
Publicado: (2021)

Clinical Significance of Free-to-Total Prostate-Specific Antigen (PSA) Ratio in Advanced Prostate Cancer Patients with PSA Less than 0.1 ng/ml after Hormone Treatment
por: Kim, Dae Il, et al.
Publicado: (2012)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
por: Vukovic, I., et al.
Publicado: (2017)

Prostate Cancer Can Be Detected Even in Patients with Decreased PSA Less than 2.5 ng/ml after Treatment of Chronic Prostatitis
por: Kim, Young Jung, et al.
Publicado: (2011)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
por: Shaida, Nadeem, et al.
Publicado: (2009)

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL
por: Okcelik, Sezgin, et al.
Publicado: (2016)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
por: Ezenwa, E.V., et al.
Publicado: (2012)

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
por: Zhou, Yongqiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_degnfj4bubfkqkdbck1ig39154